On the other hand, for NSCLC patients whose tumors lack druggable driver alternations, immunotherapy in the form of immune checkpoint inhibitors (ICIs) has emerged as a durable treatment option for patients with high tumor programmed cell death—ligand 1 (PD-L1) expression. Here, CD274 is linked to non-small cell lung carcinoma.